Literature DB >> 461280

Bile acid, neutral sterol and faecal fat excretion in subjects treated with fenfluramine and its relationship to fenfluramine-induced diarrhoea.

M S Sian, A J Rains.   

Abstract

Bile acid, neutral sterol and faecal fat excretion was studied over a period of 9 weeks in a group of 16 healthy subjects before, during and after administration of fenfluramine. Statistical analysis revealed a significant increase in bile acid excretion during the drug phase (P less than 0.02); and during recovery period of 3 weeks (P less than 0.05). Faecal neutral sterol, as the total of coprostanol and cholesterol elimination was also enhanced after fenfluramine. Coprostanol was replaced by cholesterol in 12 subjects. Faecal fat was studied in 6 subjects, the excretion increased during the drug phase (P less than 0.05), and remained elevated during the post-drug period (P less than 0.01). The composition of the bile acids remained unaltered in all the subjects except 3 who had a fenfluramine-induced watery diarrhoea; and these excreted chenodeoxy and cholic together with smaller amounts of secondary bile acids. A higher excretion of bile acids was found in the 8 overweight subjects (P less than 0.01) before ministration of fenfluramine. These results are discussed in an attempt to correlate the effect of fenfluramine with changes in bile acid and neutral sterol excretion, and its relationship to fenfluramine-induced diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 461280      PMCID: PMC2425397          DOI: 10.1136/pgmj.55.641.180

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

1.  IDENTIFICATION AND QUANTIFICATION OF NEUTRAL FECAL STEROIDS BY GAS-LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY: STUDIES OF HUMAN EXCRETION DURING TWO DIETARY REGIMENS.

Authors:  P ENEROTH; K HELLSTROEM; R RYHAGE
Journal:  J Lipid Res       Date:  1964-04       Impact factor: 5.922

2.  The effects of fenfluramine and 780SE on fat absorption.

Authors:  E Evans; D S Miller; P D Samuel; W L Burland
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

3.  Rapid method for the determination of fat in feces.

Authors:  J H VAN DE KAMER; H TEN BOKKEL HUININK; H A WEYERS
Journal:  J Biol Chem       Date:  1949-01       Impact factor: 5.157

4.  Effect of fenfluramine on blood-lipids in man.

Authors:  G L Pawan
Journal:  Lancet       Date:  1969-03-08       Impact factor: 79.321

5.  Differences in bile acid excretion in subjects with hypercholesterolaemia, hypertriglyceridaemia and overweight.

Authors:  P J Nestel; J D Hunter
Journal:  Aust N Z J Med       Date:  1974-10

6.  Faecal bile acids and neutral steroids in patients with ileal dysfunction.

Authors:  W D Mitchell; M A Eastwood
Journal:  Scand J Gastroenterol       Date:  1972       Impact factor: 2.423

7.  The effect of fenfluramine on glucose tolerance, insulin, lipid and lipoprotein levels in patients with peripheral arterial disease.

Authors:  B P Bliss; C J Kirk; R G Newall
Journal:  Postgrad Med J       Date:  1972-07       Impact factor: 2.401

8.  Toxic and therapeutic effects of EMTP in obesity.

Authors:  D R Hollingsworth; T T Amatruda
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

9.  The effect of fenfluramine on obesity and plasma lipids of patients with renal allografts.

Authors:  S A Tomlinson; J G Lines; M A Greenfield
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

10.  Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man.

Authors:  H S Mekjian; S F Phillips; A F Hofmann
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

View more
  1 in total

1.  Experimental colonic carcinogenesis: changes in faecal bile acids after promotion of intestinal tumours by small bowel resection in the rat.

Authors:  A P Savage; M S Sian; J L Matthews; S R Bloom; T Cooke
Journal:  Gut       Date:  1988-04       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.